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10% for head and neck and 4.5% for pancreas, in agreement 
with respective LEM-based prescription doses, adopted in our 
protocols. Deviations are expected to be close to zero around 
a prescription DRBE = 5 Gy (RBE). Target under-dosage was 
shown in LEM-based optimized plans, when uncorrected DRBE 
were prescribed.  
 
Conclusion: The delivery of a voxel by voxel iso-effective 
plan, if different RBE models are employed, is not feasible; it 
is however possible to minimize differences in dose deposited 
in the target. Dose prescription is a clinical task which 
ultimately depends only on the radiation oncologist clinical 
decision; in this study we made an attempt to avoid 
systematic errors which could potentially compromise tumor 
control. Initial clinical data on local control of adenoid cystic 
carcinoma treated in our facility confirms the validity of this 
approach. 
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Purpose or Objective: To assess clinical and dose factors 
affecting the incidence of urinary symptoms between 6 and 
24 months after therapy completion in patients treated with 
radical RT for prostate cancer. 
 
Material and Methods: This study examined the dataset of a 
prospective study with patients treated with conventional 
(74-80 Gy at 1.8-2 Gy/fr) or moderately hypofractionated RT 
(65-75.2 Gy at 2.2-2.7 Gy/fr) in 5 fractions per week. Clinical 
factors were collected for each patient: comorbidities, drugs, 
hormone therapies, previous surgeries, smoking, alcohol, 
age, and body mass index. Bladder DVHs were corrected with 
alfa/beta=3Gy. Urinary symptoms were evaluated through 
the IPSS (International Prostate Symptom Score) and ICIQ 
(International Consultation on Incontinence Modular 
Questionnaire short form) questionnaires filled in by the 
patients at start/end of RT and every 6 months until 5 years 
of follow up. We considered the sum of the 7 IPSS questions 
and the sum of questions 3-4 of ICIQ for the two endpoints: 1) 
IPSS≥15 and 2) ICIQ34>=4 at least once between 6 and 24 
months after RT. The best predictors to be included in the 
logistic regression model were identified through backward 
feature selections on 1000 bootstrap resamplings (the 
reported NArea identifies the weighted occurrences of the 
variables at the leading positions); then multivariate 
regressions on 1000 bootstrap resamplings were employed to 
compute the odds ratio distributions of the selected 
variables. 
 
Results: 539 patients were enrolled: dose parameters and 
toxicity data at baseline and between 6-24 months were 
available for 195 (IPSS) and 197 (ICIQ) patients. 158/195 
(81%) and 150/158 (95%) patients did not show toxicity at 
baseline (IPSS<=12 and ICIQ3=0, respectively). At 6-24 
months, the incidence of IPSS>=15 was 42/158 (27%) and of 
ICIQ34>=4 was 34/150 (23%). A 6-variable model (AUC=0.86) 
was considered for IPSS: basal IPSS (NArea=0.72, OR=1.51) 
and the change of IPSS at RT end (deltaIPSS) (NArea=0.74, 
OR=1.16) were the leading risk factors. V62Gy was also a risk 
factor (NArea=0.36, OR=1.04), while the analogues and 
antiandrogens in hormone therapies were found protective 
(NArea=0.34, OR=0.38) and risk parameters (NArea=0.29, 
OR=2.57), respectively. For ICIQ, a backward feature 
selection was employed: antiaggregants (OR=2.16, p=0.11), 
antiandrogens (OR=2.03, p=0.08) and age (OR=1.09, p=0.04) 
were found as risk factors, whereas none dose parameter was 
found correlated with toxicity. 
 
 
 
 
 
Conclusion: The analysis shows an important correlation of 
urinary toxicities at 6-24 months with the patient urinary 
condition at baseline and, also, with the acute worsening of 
symptoms. Interestingly, hormone therapies with analogues 
(protective) and antiandrogens (risk) showed an opposite 
behaviour for late toxicities. The absence of correlation of 
incontinence with dose might be due to the very low number 
of severe toxicities registered. 
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Purpose or Objective: Differential diagnosis between benign 
changes on follow-up CT from progression or recurrence is a 
difficult task in highly conformal RT because areas of dense 
consolidation usually develop around the treated tumor. The 
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prediction of radiation-induced changes in lung density on 
follow-up CT can be of help with differential diagnosis. The 
goal of this work was to develop a Normal Tissue 
Complication Probability (NTCP) model for voxel by voxel 
prediction of changes in lung density on CT scans of patients 
treated with IMRT. 
 
Material and Methods: 20 patients were treated with 
fractionated IMRT (60 Gy/25 fractions) or SBRT with Helical 
Tomotherapy (40-52 Gy in 5-10 fractions) for lung 
tumors.Follow-up CT scans were acquired at 6 months after 
the end of RT and were registered with pre-treatment scans 
using rigid (6 degrees of freedom) followed by a b-spline (> 
27 degrees of freedom) deformable registration performed 
using the 3D Slicer freeware software suite. Registration 
accuracy was assessed by comparing the calculated 
displacement at bifurcation points with the displacement 
measured on unregistered images. Registration was repeated 
when the difference was more than 1 cm. Voxels Hounsfield 
units were converted into relative electron density (RED) 
using in-phantom measured CT-RED curves. The change in 
RED between the two images was calculated for each voxel 
within the healthy lung tissue, defined as combined lungs 
after subtraction of PTV, among all the patients. Voxels RED 
changes versus absolute dose were fitted among all patients 
using a function similar to Lyman NTCP model. Model 
parameters were D0.5, the dose giving 0.5 increase in 
relative electron density and m, the slope of the dose-
response curve. No correction was used for fractionation of 
the treatments. Predictive power of model was assessed by a 
test of correlation of measured and predicted RED changes. 
 
Results: The dose giving an increase of 0.5 RED estimated 
from fitting of lung density changes was D0.5 = 99.5 Gy 
(95%CI = 84.0-114.9 Gy). Slope of dose response, m, was 
0.338 (95%CI = 0.296-0.380). The correlation test shows that 
predicted and measured RED changes were statistically 
strongly correlated (p<0.001). 
 
Conclusion: The model describes well the change in RED in 
follow-up CT scans of IMRT patients and can be used to 
generate maps of predicted RED to be visualized on follow-up 
CT scans, as a support for differential diagnosis between 
benign changes from progression or recurrence. 
 
PO-0877  
Baseline CT image and isodose shape features improve 
prognostic models for dyspnea after RT in NSCLC 
G. Defraene
1KU Leuven - University of Leuven, Experimental Radiation 
Oncology, Leuven, Belgium 
1, W. Van Elmpt2, D. De Ruysscher3 
2Maastricht University Medical Centre, Department of 
Radiation Oncology Maastro-Clinic, Maastricht, The 
Netherlands 
3University Hospitals Leuven, Department of Radiation 
Oncology, Leuven, Belgium 
 
Purpose or Objective: Lung toxicity prediction models 
currently rely on dosimetric factors as mean lung dose (MLD) 
or V20 (volume of lung receiving more than 20 Gy), and 
clinical factors (e.g. age, smoking history). With a 
consistently reported area under the curve (AUC) around 0.6 
these models are limited in discriminating between low- and 
high-risk patients before treatment. The present study aims 
at designing a better prognostic model by broadening the 
search for prognostic factors using a radiomics approach both 
on the imaging and dosimetric level. For this, CT image 
features of lung tissue and isodose shape measures were 
explored to predict the endpoint of dyspnea. 
 
Material and Methods: 80 stage I-IV non-small cell lung 
cancer patients were included. Prescription dose was 66Gy, 
in fractions of 2.75 Gy sequentially or 2 Gy concurrent with 
chemotherapy. Maximal increase in CTCAE 4.0 dyspnea score 
in the first 6 months after the end of radiotherapy was 
retrospectively recorded with respect to baseline status. 
30 lung image features were extracted from the baseline 
free-breathing planning CT: 10 intensity-based features 
(derived from the histogram of intensities), and the mean 
value and standard deviation of 10 texture features (from the 
co-occurrence matrix, neighbourhood gray tone difference 
matrix (NGTDM) and neighbouring gray level dependence 
matrix (NGLDM) categories). All features were calculated 
within each of the isodose volumes V5, V20 and V40 of the 
lung excluding the GTV structure. Additionally 15 shape and 
location features of these isodose volumes were collected: 
volume, bounding box dimensions, centroid coordinates and 
compactness. Other features included age, smoking status, 
chemotherapy regimen, treatment modulation, heart Dmax 
and Dmean. 
All combinations of the 5 most significant features resulting 
from a univariate logistic regression analysis were tested in 
multivariate setting (likelihood ratio test between nested 
models). 
 
Results: Dyspnea increase grade >= 2 was present in 13.8% of 
patients. For an increase of at least 1 grade, this was 38.8%.  
In univariate modeling, several image and isodose shape 
features performed significantly better than MLD for both 
endpoints (Table 1). The resulting classifier for dyspnea 
increase grade >= 1 was based on the texture feature ‘small 
number emphasis’ and the V40 isodose antero-posterior 
dimension (AUC=0.71). The dyspnea increase grade >= 2 
classifier was based on mean heart dose and antero-posterior 
dimension of the V20 isodose (AUC=0.71). 
 
 
Conclusion: A radiomics analysis with image and isodose 
features yielded promising prognostic models for dyspnea 
compared to the classical MLD-based model. Validation on a 
recently available large multicentric database will be 
performed by the time of the congress, which will allow the 
selection of the most robust model. 
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Purpose or Objective: Intra-fraction motion of the prostate 
is a known phenomenon that degrades the delivered dose to 
